Research programme: small molecule anti-psychotic therapeutics - Solvay/Wyeth
Latest Information Update: 02 Dec 2008
At a glance
- Originator Solvay Pharmaceuticals; Wyeth
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 15 Jan 2007 Preclinical trials in Psychotic disorders in USA (unspecified route)